EUCTR2007-005958-23-DE进行中（未招募）不适用
A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500 Unit Presentation for the Treatment of Glabellar Lines
Ipsen Group, SCRAS Institut Henri Beaufour0 个研究点开始时间: 2007年12月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects between 18 and 65 years of age;
- •2. Moderate to severe vertical glabellar lines at maximum frown (score of 2 or 3 by the subject's static self-assessment and confirmed by the Investigator’s live assessment, using a 4-point categorical scale (no wrinkles [0], mild wrinkles [1], moderate wrinkles [2], or severe wrinkles [3]);
- •3. Negative pregnancy test result for females of childbearing potential;
- •4. Time and ability to complete the study and comply with instructions;
- •5. Understanding of the study and the contents of the informed consent documents. All subjects must provide written informed consent before enrolling into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Previous treatment with Dysport or any other botulinum toxin or toxin treatment to any areas of the body at any time prior to the study or planned during the study;
- •(2) Inability to substantially lessen glabellar lines by physically spreading them apart;
- •(3) Concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication;
- •(4) Active infection in the glabellar area (e.g., acute acne lesions);
- •(5) Pregnant women, nursing mothers, or women who are planning pregnancy during the study, or who think that they might be pregnant at the start of the study.
- •(6) Current history of chronic drug or alcohol abuse;
- •(7) Enrolment in any active study involving the use of investigational devices or drugs within 90 days of the screening visit;
- •(8) Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin;
- •(9) Neuromuscular junctional disorders (e.g., myasthenia gravis);
- •(10) Known allergy or hypersensitivity to any botulinum toxin or any component of Reloxin or Dysport;
- •(11) Concurrent use of medications that affect neuromuscular transmission, such as lincosamides, polymyxins, and aminoglycoside antibiotics affecting the striated muscle;
- •(12) Presence of any other condition (e.g., neuromuscular disorder or other disorder that could interfere with neuromuscular function) or circumstance that, in the judgment of the Investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study;
- •(13) Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- •(14) Subjects must not be confined in an institution due to court or administrative order.
研究者
相似试验
招募中
2 期
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)on-Small Cell Lung Cancer with brain metastasesNon-Small Cell Lung Cancer with brain metastasesCancer - Lung - Non small cellCancer - BrainACTRN12610000560099YM BioSciences Inc.88
进行中（未招募）
1 期
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-GBAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-CZAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerEUCTR2005-003443-31-BEAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-DEAstraZeneca AB210